Breaking News, Trials & Filings

Trials & Filings in Brief: Oct. 9, 2013

Alkermes, Allegro, Bayer, BDSI, Medivir, Pfizer, Portola, and The Medicines Company

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I Medivir posts new seven-day data of MIV-711 in osteoarthritis . . . read more Portola begins proof-of-concept for SyK/JAK inhibitor . . . read more Phase II Alkermes aligns with FDA on development plans . . . read more Allegro cleared for ophthalmic trials . . . read more Phase III Pfizer releases topline data for JAK inhibitor . . . read more TMC enrolls first Angiomax PEI patient . . . read more Filings Bayer PAH/CTEPH drug approved . . . read more BDSI Files Bunavail NDA . . . ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters